Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

09 Jan 2019

• By Emily Hayes, Jung Won Shin, Ian Haydock, Anju Ghangurde, and Jo Shorthouse

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

More from Deals

More from Business